Sanofi will overhaul its Executive Committee effective September 1, 2026. The restructuring aims to streamline leadership for the company’s next strategic phase.
General Counsel Roy Papatheodorou will depart the company. Olivier Charmeil will transition from head of General Medicines to Strategic Projects Advisor to the CEO.
The Finance department will now incorporate Business Development and M&A functions. Vaccines head Thomas Triomphe will assume additional responsibility for operations in China.